Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients

View Full Paper
Ask AI
Bookmark
Share

Authors

JMJesús F. San MiguelSBSara BringhenMMMaría‐Victoria Mateos

Discussion

Loading...

Member takes

Overview

Pooled analysis shows that isa-vrd improves overall response rate in patients with frailty and multiple myeloma.

Key Points

  • Complete response rates were noted at 72% in ≤75 years and 67% in >75 years, indicating consistent efficacy.
  • Analysis combined data from IMROZ and phase 1b studies, incorporating patients across various age groups.
  • Pooled patient data included 336 individuals, revealing significant results for overall response and treatment safety.
  • Frail patients experienced similar efficacy and safety profiles when treated with isa-vrd, supporting its broad applicability.

Cite This Study

Miguel et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df3ehttps://doi.org/10.1182/blood-2025-2267
View Full Paper
Ask AI
Bookmark
Share